Global Oxaliplatin
Global Oxaliplatin

Oxaliplatin Comprehensive Study by Type (Mannitol, Glucose Solution, Lactose Solution, Others), Application (Colorectal Cancer (XELOX), Pancreatic Cancer, Gastroesophageal Cancer, Testicular Cancer, Cancer of Unknown Primary Origin, Ovarian Cancer), Dosage Form (Sterile Lyophilized Powder (50mg) Players and Region - Global Market Outlook to 2024

Oxaliplatin Market Segmented into XX Submarkets. | Forecast Years: 2019- 2024  

Oct 2019 Edition 204 Pages 200 Tables & Figures
  • Summary
  • Market Segments
  • Table of Content
  • List of Tables & Figures
  • Companies Mentioned
Oxaliplatin Market Scope
Oxaliplatin is a platinum-based drug used in the treatment of stage III colon cancer, who have undergone complete resection of the primary tumor and also for the treatment of advanced colorectal cancer. This medicine canít take on high allergic reactions, Neuropathy, Pulmonary Toxicity, Hepatotoxicity, and Pregnancy. It is commonly known as a trading name as Eloxatin.

The market study is being classified by Type (Mannitol, Glucose Solution, Lactose Solution and Others), by Application (Colorectal Cancer (XELOX), Pancreatic Cancer, Gastroesophageal Cancer, Testicular Cancer, Cancer of Unknown Primary Origin and Ovarian Cancer) and major geographies with country level break-up.

The global Oxaliplatin market is highly competitive and consists of some key players. In terms of market share, few of the key players presently dominate the global market. These market players are leveraging on strategic collaborative creativities to intensification their market share and escalation their profitability. Research Analyst at AMA predicts that China Players will contribute to the maximum growth of Global Oxaliplatin market throughout the predicted period.

Sanofi (France), Yakult honsha (Japan), Dr. Reddy's Laboratories (India), Sun Pharmaceutical (India), Teva Pharmaceutical Industries (Israel), Fresenius Kabi (Germany), Hospira (United States), Mylan (United States), Jiangsu Hengrui Medicine (China) and Nanjing Pharmaceutical Factory (China) are some of the key players profiled in the study. Additionally, the Players which are also part of the research are Hisun Pharmaceutical (United States), Chia Tai-Tianqing Pharmaceutical Holdings Co., Ltd (China), Jiangsu Aosaikang Pharmaceutical (China) and Qilu Pharmaceutical (China).

Segmentation Overview
AdvanceMarketAnalytics has segmented the market of Global Oxaliplatin market by Type, Application and Region.

On the basis of geography, the market of Oxaliplatin has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico).

In Nov 2018, Merck announced the approval of the KEYTRUDA drug from the United States Food and Drug Administration. KEYTRUDA is defined for the treatment of adult and pediatric patients. It is used in colorectal cancer that has progressed the treatments with oxaliplatin.


Market Trend
  • Increasing Number of Research and Development Activities
  • Technology Advancement in Manufacturing Equipment

Market Drivers
  • Increase Number of Cancer Patients across the Globe, But Majorly in the United States Region

Opportunities
  • Increasing Number of Drug Manufacturing Companies
  • Rise in Distribution Channels among Emerging Economies

Restraints
  • Stringent Government Regulations

Challenges
  • Rising Concern towards High Number of Side Effects


Key Target Audience
Venture Capitalists and Private Equity Firms, New Entrants/Investors, Analysts and Strategic Business Planners, Oxaliplatin Manufacturers, Suppliers and Distributors, Raw Material Suppliers, Government Regulatory and Research Organizations and End-Use Industries

Customization available in this Study:
The Study can be customized to meet your requirements. Please connect with our representative, who will ensure you get a report that suits your needs.
Data related to EXIM [Export- Import], production & consumption by country or regional level break-up can be provided based on client request**
** Confirmation on availability of data would be informed prior purchase
Report Objectives / Segmentation Covered
By Type
  • Mannitol
  • Glucose Solution
  • Lactose Solution
  • Others
By Application
  • Colorectal Cancer (XELOX)
  • Pancreatic Cancer
  • Gastroesophageal Cancer
  • Testicular Cancer
  • Cancer of Unknown Primary Origin
  • Ovarian Cancer
By Dosage Form
  • Sterile Lyophilized Powder (50mg

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Increase Number of Cancer Patients across the Globe, But Majorly in the United States Region
    • 3.3. Market Challenges
      • 3.3.1. Rising Concern towards High Number of Side Effects
    • 3.4. Market Trends
      • 3.4.1. Increasing Number of Research and Development Activities
      • 3.4.2. Technology Advancement in Manufacturing Equipment
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Oxaliplatin, by Type, Application, Dosage Form and Region (value, volume and price ) (2013-2018)
    • 5.1. Introduction
    • 5.2. Global Oxaliplatin (Value)
      • 5.2.1. Global Oxaliplatin by: Type (Value)
        • 5.2.1.1. Mannitol
        • 5.2.1.2. Glucose Solution
        • 5.2.1.3. Lactose Solution
        • 5.2.1.4. Others
      • 5.2.2. Global Oxaliplatin by: Application (Value)
        • 5.2.2.1. Colorectal Cancer (XELOX)
        • 5.2.2.2. Pancreatic Cancer
        • 5.2.2.3. Gastroesophageal Cancer
        • 5.2.2.4. Testicular Cancer
        • 5.2.2.5. Cancer of Unknown Primary Origin
        • 5.2.2.6. Ovarian Cancer
      • 5.2.3. Global Oxaliplatin by: Dosage Form (Value)
        • 5.2.3.1. Sterile Lyophilized Powder (50mg
      • 5.2.4. Global Oxaliplatin Region
        • 5.2.4.1. South America
          • 5.2.4.1.1. Brazil
          • 5.2.4.1.2. Argentina
          • 5.2.4.1.3. Rest of South America
        • 5.2.4.2. Asia Pacific
          • 5.2.4.2.1. China
          • 5.2.4.2.2. Japan
          • 5.2.4.2.3. India
          • 5.2.4.2.4. South Korea
          • 5.2.4.2.5. Taiwan
          • 5.2.4.2.6. Australia
          • 5.2.4.2.7. Rest of Asia-Pacific
        • 5.2.4.3. Europe
          • 5.2.4.3.1. Germany
          • 5.2.4.3.2. France
          • 5.2.4.3.3. Italy
          • 5.2.4.3.4. United Kingdom
          • 5.2.4.3.5. Netherlands
          • 5.2.4.3.6. Rest of Europe
        • 5.2.4.4. MEA
          • 5.2.4.4.1. Middle East
          • 5.2.4.4.2. Africa
        • 5.2.4.5. North America
          • 5.2.4.5.1. United States
          • 5.2.4.5.2. Canada
          • 5.2.4.5.3. Mexico
    • 5.3. Global Oxaliplatin (Volume)
      • 5.3.1. Global Oxaliplatin by: Type (Volume)
        • 5.3.1.1. Mannitol
        • 5.3.1.2. Glucose Solution
        • 5.3.1.3. Lactose Solution
        • 5.3.1.4. Others
      • 5.3.2. Global Oxaliplatin by: Application (Volume)
        • 5.3.2.1. Colorectal Cancer (XELOX)
        • 5.3.2.2. Pancreatic Cancer
        • 5.3.2.3. Gastroesophageal Cancer
        • 5.3.2.4. Testicular Cancer
        • 5.3.2.5. Cancer of Unknown Primary Origin
        • 5.3.2.6. Ovarian Cancer
      • 5.3.3. Global Oxaliplatin by: Dosage Form (Volume)
        • 5.3.3.1. Sterile Lyophilized Powder (50mg
      • 5.3.4. Global Oxaliplatin Region
        • 5.3.4.1. South America
          • 5.3.4.1.1. Brazil
          • 5.3.4.1.2. Argentina
          • 5.3.4.1.3. Rest of South America
        • 5.3.4.2. Asia Pacific
          • 5.3.4.2.1. China
          • 5.3.4.2.2. Japan
          • 5.3.4.2.3. India
          • 5.3.4.2.4. South Korea
          • 5.3.4.2.5. Taiwan
          • 5.3.4.2.6. Australia
          • 5.3.4.2.7. Rest of Asia-Pacific
        • 5.3.4.3. Europe
          • 5.3.4.3.1. Germany
          • 5.3.4.3.2. France
          • 5.3.4.3.3. Italy
          • 5.3.4.3.4. United Kingdom
          • 5.3.4.3.5. Netherlands
          • 5.3.4.3.6. Rest of Europe
        • 5.3.4.4. MEA
          • 5.3.4.4.1. Middle East
          • 5.3.4.4.2. Africa
        • 5.3.4.5. North America
          • 5.3.4.5.1. United States
          • 5.3.4.5.2. Canada
          • 5.3.4.5.3. Mexico
    • 5.4. Global Oxaliplatin (Price)
      • 5.4.1. Global Oxaliplatin by: Type (Price)
  • 6. Oxaliplatin: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2018)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Sanofi (France)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Yakult honsha (Japan)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Dr. Reddy's Laboratories (India)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Sun Pharmaceutical (India)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Teva Pharmaceutical Industries (Israel)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Fresenius Kabi (Germany)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Hospira (United States)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Mylan (United States)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Jiangsu Hengrui Medicine (China)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Nanjing Pharmaceutical Factory (China)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global Oxaliplatin Sale, by Type, Application, Dosage Form and Region (value, volume and price ) (2019-2024)
    • 7.1. Introduction
    • 7.2. Global Oxaliplatin (Value)
      • 7.2.1. Global Oxaliplatin by: Type (Value)
        • 7.2.1.1. Mannitol
        • 7.2.1.2. Glucose Solution
        • 7.2.1.3. Lactose Solution
        • 7.2.1.4. Others
      • 7.2.2. Global Oxaliplatin by: Application (Value)
        • 7.2.2.1. Colorectal Cancer (XELOX)
        • 7.2.2.2. Pancreatic Cancer
        • 7.2.2.3. Gastroesophageal Cancer
        • 7.2.2.4. Testicular Cancer
        • 7.2.2.5. Cancer of Unknown Primary Origin
        • 7.2.2.6. Ovarian Cancer
      • 7.2.3. Global Oxaliplatin by: Dosage Form (Value)
        • 7.2.3.1. Sterile Lyophilized Powder (50mg
      • 7.2.4. Global Oxaliplatin Region
        • 7.2.4.1. South America
          • 7.2.4.1.1. Brazil
          • 7.2.4.1.2. Argentina
          • 7.2.4.1.3. Rest of South America
        • 7.2.4.2. Asia Pacific
          • 7.2.4.2.1. China
          • 7.2.4.2.2. Japan
          • 7.2.4.2.3. India
          • 7.2.4.2.4. South Korea
          • 7.2.4.2.5. Taiwan
          • 7.2.4.2.6. Australia
          • 7.2.4.2.7. Rest of Asia-Pacific
        • 7.2.4.3. Europe
          • 7.2.4.3.1. Germany
          • 7.2.4.3.2. France
          • 7.2.4.3.3. Italy
          • 7.2.4.3.4. United Kingdom
          • 7.2.4.3.5. Netherlands
          • 7.2.4.3.6. Rest of Europe
        • 7.2.4.4. MEA
          • 7.2.4.4.1. Middle East
          • 7.2.4.4.2. Africa
        • 7.2.4.5. North America
          • 7.2.4.5.1. United States
          • 7.2.4.5.2. Canada
          • 7.2.4.5.3. Mexico
    • 7.3. Global Oxaliplatin (Volume)
      • 7.3.1. Global Oxaliplatin by: Type (Volume)
        • 7.3.1.1. Mannitol
        • 7.3.1.2. Glucose Solution
        • 7.3.1.3. Lactose Solution
        • 7.3.1.4. Others
      • 7.3.2. Global Oxaliplatin by: Application (Volume)
        • 7.3.2.1. Colorectal Cancer (XELOX)
        • 7.3.2.2. Pancreatic Cancer
        • 7.3.2.3. Gastroesophageal Cancer
        • 7.3.2.4. Testicular Cancer
        • 7.3.2.5. Cancer of Unknown Primary Origin
        • 7.3.2.6. Ovarian Cancer
      • 7.3.3. Global Oxaliplatin by: Dosage Form (Volume)
        • 7.3.3.1. Sterile Lyophilized Powder (50mg
      • 7.3.4. Global Oxaliplatin Region
        • 7.3.4.1. South America
          • 7.3.4.1.1. Brazil
          • 7.3.4.1.2. Argentina
          • 7.3.4.1.3. Rest of South America
        • 7.3.4.2. Asia Pacific
          • 7.3.4.2.1. China
          • 7.3.4.2.2. Japan
          • 7.3.4.2.3. India
          • 7.3.4.2.4. South Korea
          • 7.3.4.2.5. Taiwan
          • 7.3.4.2.6. Australia
          • 7.3.4.2.7. Rest of Asia-Pacific
        • 7.3.4.3. Europe
          • 7.3.4.3.1. Germany
          • 7.3.4.3.2. France
          • 7.3.4.3.3. Italy
          • 7.3.4.3.4. United Kingdom
          • 7.3.4.3.5. Netherlands
          • 7.3.4.3.6. Rest of Europe
        • 7.3.4.4. MEA
          • 7.3.4.4.1. Middle East
          • 7.3.4.4.2. Africa
        • 7.3.4.5. North America
          • 7.3.4.5.1. United States
          • 7.3.4.5.2. Canada
          • 7.3.4.5.3. Mexico
    • 7.4. Global Oxaliplatin (Price)
      • 7.4.1. Global Oxaliplatin by: Type (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Oxaliplatin: by Type(USD Million)
  • Table 2. Oxaliplatin Mannitol , by Region USD Million (2013-2018)
  • Table 3. Oxaliplatin Glucose Solution , by Region USD Million (2013-2018)
  • Table 4. Oxaliplatin Lactose Solution , by Region USD Million (2013-2018)
  • Table 5. Oxaliplatin Others , by Region USD Million (2013-2018)
  • Table 6. Oxaliplatin: by Application(USD Million)
  • Table 7. Oxaliplatin Colorectal Cancer (XELOX) , by Region USD Million (2013-2018)
  • Table 8. Oxaliplatin Pancreatic Cancer , by Region USD Million (2013-2018)
  • Table 9. Oxaliplatin Gastroesophageal Cancer , by Region USD Million (2013-2018)
  • Table 10. Oxaliplatin Testicular Cancer , by Region USD Million (2013-2018)
  • Table 11. Oxaliplatin Cancer of Unknown Primary Origin , by Region USD Million (2013-2018)
  • Table 12. Oxaliplatin Ovarian Cancer , by Region USD Million (2013-2018)
  • Table 13. Oxaliplatin: by Dosage Form(USD Million)
  • Table 14. Oxaliplatin Sterile Lyophilized Powder (50mg , by Region USD Million (2013-2018)
  • Table 15. South America Oxaliplatin, by Country USD Million (2013-2018)
  • Table 16. South America Oxaliplatin, by Type USD Million (2013-2018)
  • Table 17. South America Oxaliplatin, by Application USD Million (2013-2018)
  • Table 18. South America Oxaliplatin, by Dosage Form USD Million (2013-2018)
  • Table 19. Brazil Oxaliplatin, by Type USD Million (2013-2018)
  • Table 20. Brazil Oxaliplatin, by Application USD Million (2013-2018)
  • Table 21. Brazil Oxaliplatin, by Dosage Form USD Million (2013-2018)
  • Table 22. Argentina Oxaliplatin, by Type USD Million (2013-2018)
  • Table 23. Argentina Oxaliplatin, by Application USD Million (2013-2018)
  • Table 24. Argentina Oxaliplatin, by Dosage Form USD Million (2013-2018)
  • Table 25. Rest of South America Oxaliplatin, by Type USD Million (2013-2018)
  • Table 26. Rest of South America Oxaliplatin, by Application USD Million (2013-2018)
  • Table 27. Rest of South America Oxaliplatin, by Dosage Form USD Million (2013-2018)
  • Table 28. Asia Pacific Oxaliplatin, by Country USD Million (2013-2018)
  • Table 29. Asia Pacific Oxaliplatin, by Type USD Million (2013-2018)
  • Table 30. Asia Pacific Oxaliplatin, by Application USD Million (2013-2018)
  • Table 31. Asia Pacific Oxaliplatin, by Dosage Form USD Million (2013-2018)
  • Table 32. China Oxaliplatin, by Type USD Million (2013-2018)
  • Table 33. China Oxaliplatin, by Application USD Million (2013-2018)
  • Table 34. China Oxaliplatin, by Dosage Form USD Million (2013-2018)
  • Table 35. Japan Oxaliplatin, by Type USD Million (2013-2018)
  • Table 36. Japan Oxaliplatin, by Application USD Million (2013-2018)
  • Table 37. Japan Oxaliplatin, by Dosage Form USD Million (2013-2018)
  • Table 38. India Oxaliplatin, by Type USD Million (2013-2018)
  • Table 39. India Oxaliplatin, by Application USD Million (2013-2018)
  • Table 40. India Oxaliplatin, by Dosage Form USD Million (2013-2018)
  • Table 41. South Korea Oxaliplatin, by Type USD Million (2013-2018)
  • Table 42. South Korea Oxaliplatin, by Application USD Million (2013-2018)
  • Table 43. South Korea Oxaliplatin, by Dosage Form USD Million (2013-2018)
  • Table 44. Taiwan Oxaliplatin, by Type USD Million (2013-2018)
  • Table 45. Taiwan Oxaliplatin, by Application USD Million (2013-2018)
  • Table 46. Taiwan Oxaliplatin, by Dosage Form USD Million (2013-2018)
  • Table 47. Australia Oxaliplatin, by Type USD Million (2013-2018)
  • Table 48. Australia Oxaliplatin, by Application USD Million (2013-2018)
  • Table 49. Australia Oxaliplatin, by Dosage Form USD Million (2013-2018)
  • Table 50. Rest of Asia-Pacific Oxaliplatin, by Type USD Million (2013-2018)
  • Table 51. Rest of Asia-Pacific Oxaliplatin, by Application USD Million (2013-2018)
  • Table 52. Rest of Asia-Pacific Oxaliplatin, by Dosage Form USD Million (2013-2018)
  • Table 53. Europe Oxaliplatin, by Country USD Million (2013-2018)
  • Table 54. Europe Oxaliplatin, by Type USD Million (2013-2018)
  • Table 55. Europe Oxaliplatin, by Application USD Million (2013-2018)
  • Table 56. Europe Oxaliplatin, by Dosage Form USD Million (2013-2018)
  • Table 57. Germany Oxaliplatin, by Type USD Million (2013-2018)
  • Table 58. Germany Oxaliplatin, by Application USD Million (2013-2018)
  • Table 59. Germany Oxaliplatin, by Dosage Form USD Million (2013-2018)
  • Table 60. France Oxaliplatin, by Type USD Million (2013-2018)
  • Table 61. France Oxaliplatin, by Application USD Million (2013-2018)
  • Table 62. France Oxaliplatin, by Dosage Form USD Million (2013-2018)
  • Table 63. Italy Oxaliplatin, by Type USD Million (2013-2018)
  • Table 64. Italy Oxaliplatin, by Application USD Million (2013-2018)
  • Table 65. Italy Oxaliplatin, by Dosage Form USD Million (2013-2018)
  • Table 66. United Kingdom Oxaliplatin, by Type USD Million (2013-2018)
  • Table 67. United Kingdom Oxaliplatin, by Application USD Million (2013-2018)
  • Table 68. United Kingdom Oxaliplatin, by Dosage Form USD Million (2013-2018)
  • Table 69. Netherlands Oxaliplatin, by Type USD Million (2013-2018)
  • Table 70. Netherlands Oxaliplatin, by Application USD Million (2013-2018)
  • Table 71. Netherlands Oxaliplatin, by Dosage Form USD Million (2013-2018)
  • Table 72. Rest of Europe Oxaliplatin, by Type USD Million (2013-2018)
  • Table 73. Rest of Europe Oxaliplatin, by Application USD Million (2013-2018)
  • Table 74. Rest of Europe Oxaliplatin, by Dosage Form USD Million (2013-2018)
  • Table 75. MEA Oxaliplatin, by Country USD Million (2013-2018)
  • Table 76. MEA Oxaliplatin, by Type USD Million (2013-2018)
  • Table 77. MEA Oxaliplatin, by Application USD Million (2013-2018)
  • Table 78. MEA Oxaliplatin, by Dosage Form USD Million (2013-2018)
  • Table 79. Middle East Oxaliplatin, by Type USD Million (2013-2018)
  • Table 80. Middle East Oxaliplatin, by Application USD Million (2013-2018)
  • Table 81. Middle East Oxaliplatin, by Dosage Form USD Million (2013-2018)
  • Table 82. Africa Oxaliplatin, by Type USD Million (2013-2018)
  • Table 83. Africa Oxaliplatin, by Application USD Million (2013-2018)
  • Table 84. Africa Oxaliplatin, by Dosage Form USD Million (2013-2018)
  • Table 85. North America Oxaliplatin, by Country USD Million (2013-2018)
  • Table 86. North America Oxaliplatin, by Type USD Million (2013-2018)
  • Table 87. North America Oxaliplatin, by Application USD Million (2013-2018)
  • Table 88. North America Oxaliplatin, by Dosage Form USD Million (2013-2018)
  • Table 89. United States Oxaliplatin, by Type USD Million (2013-2018)
  • Table 90. United States Oxaliplatin, by Application USD Million (2013-2018)
  • Table 91. United States Oxaliplatin, by Dosage Form USD Million (2013-2018)
  • Table 92. Canada Oxaliplatin, by Type USD Million (2013-2018)
  • Table 93. Canada Oxaliplatin, by Application USD Million (2013-2018)
  • Table 94. Canada Oxaliplatin, by Dosage Form USD Million (2013-2018)
  • Table 95. Mexico Oxaliplatin, by Type USD Million (2013-2018)
  • Table 96. Mexico Oxaliplatin, by Application USD Million (2013-2018)
  • Table 97. Mexico Oxaliplatin, by Dosage Form USD Million (2013-2018)
  • Table 98. Oxaliplatin Sales: by Type(K Units)
  • Table 99. Oxaliplatin Sales Mannitol , by Region K Units (2013-2018)
  • Table 100. Oxaliplatin Sales Glucose Solution , by Region K Units (2013-2018)
  • Table 101. Oxaliplatin Sales Lactose Solution , by Region K Units (2013-2018)
  • Table 102. Oxaliplatin Sales Others , by Region K Units (2013-2018)
  • Table 103. Oxaliplatin Sales: by Application(K Units)
  • Table 104. Oxaliplatin Sales Colorectal Cancer (XELOX) , by Region K Units (2013-2018)
  • Table 105. Oxaliplatin Sales Pancreatic Cancer , by Region K Units (2013-2018)
  • Table 106. Oxaliplatin Sales Gastroesophageal Cancer , by Region K Units (2013-2018)
  • Table 107. Oxaliplatin Sales Testicular Cancer , by Region K Units (2013-2018)
  • Table 108. Oxaliplatin Sales Cancer of Unknown Primary Origin , by Region K Units (2013-2018)
  • Table 109. Oxaliplatin Sales Ovarian Cancer , by Region K Units (2013-2018)
  • Table 110. Oxaliplatin Sales: by Dosage Form(K Units)
  • Table 111. Oxaliplatin Sales Sterile Lyophilized Powder (50mg , by Region K Units (2013-2018)
  • Table 112. South America Oxaliplatin Sales, by Country K Units (2013-2018)
  • Table 113. South America Oxaliplatin Sales, by Type K Units (2013-2018)
  • Table 114. South America Oxaliplatin Sales, by Application K Units (2013-2018)
  • Table 115. South America Oxaliplatin Sales, by Dosage Form K Units (2013-2018)
  • Table 116. Brazil Oxaliplatin Sales, by Type K Units (2013-2018)
  • Table 117. Brazil Oxaliplatin Sales, by Application K Units (2013-2018)
  • Table 118. Brazil Oxaliplatin Sales, by Dosage Form K Units (2013-2018)
  • Table 119. Argentina Oxaliplatin Sales, by Type K Units (2013-2018)
  • Table 120. Argentina Oxaliplatin Sales, by Application K Units (2013-2018)
  • Table 121. Argentina Oxaliplatin Sales, by Dosage Form K Units (2013-2018)
  • Table 122. Rest of South America Oxaliplatin Sales, by Type K Units (2013-2018)
  • Table 123. Rest of South America Oxaliplatin Sales, by Application K Units (2013-2018)
  • Table 124. Rest of South America Oxaliplatin Sales, by Dosage Form K Units (2013-2018)
  • Table 125. Asia Pacific Oxaliplatin Sales, by Country K Units (2013-2018)
  • Table 126. Asia Pacific Oxaliplatin Sales, by Type K Units (2013-2018)
  • Table 127. Asia Pacific Oxaliplatin Sales, by Application K Units (2013-2018)
  • Table 128. Asia Pacific Oxaliplatin Sales, by Dosage Form K Units (2013-2018)
  • Table 129. China Oxaliplatin Sales, by Type K Units (2013-2018)
  • Table 130. China Oxaliplatin Sales, by Application K Units (2013-2018)
  • Table 131. China Oxaliplatin Sales, by Dosage Form K Units (2013-2018)
  • Table 132. Japan Oxaliplatin Sales, by Type K Units (2013-2018)
  • Table 133. Japan Oxaliplatin Sales, by Application K Units (2013-2018)
  • Table 134. Japan Oxaliplatin Sales, by Dosage Form K Units (2013-2018)
  • Table 135. India Oxaliplatin Sales, by Type K Units (2013-2018)
  • Table 136. India Oxaliplatin Sales, by Application K Units (2013-2018)
  • Table 137. India Oxaliplatin Sales, by Dosage Form K Units (2013-2018)
  • Table 138. South Korea Oxaliplatin Sales, by Type K Units (2013-2018)
  • Table 139. South Korea Oxaliplatin Sales, by Application K Units (2013-2018)
  • Table 140. South Korea Oxaliplatin Sales, by Dosage Form K Units (2013-2018)
  • Table 141. Taiwan Oxaliplatin Sales, by Type K Units (2013-2018)
  • Table 142. Taiwan Oxaliplatin Sales, by Application K Units (2013-2018)
  • Table 143. Taiwan Oxaliplatin Sales, by Dosage Form K Units (2013-2018)
  • Table 144. Australia Oxaliplatin Sales, by Type K Units (2013-2018)
  • Table 145. Australia Oxaliplatin Sales, by Application K Units (2013-2018)
  • Table 146. Australia Oxaliplatin Sales, by Dosage Form K Units (2013-2018)
  • Table 147. Rest of Asia-Pacific Oxaliplatin Sales, by Type K Units (2013-2018)
  • Table 148. Rest of Asia-Pacific Oxaliplatin Sales, by Application K Units (2013-2018)
  • Table 149. Rest of Asia-Pacific Oxaliplatin Sales, by Dosage Form K Units (2013-2018)
  • Table 150. Europe Oxaliplatin Sales, by Country K Units (2013-2018)
  • Table 151. Europe Oxaliplatin Sales, by Type K Units (2013-2018)
  • Table 152. Europe Oxaliplatin Sales, by Application K Units (2013-2018)
  • Table 153. Europe Oxaliplatin Sales, by Dosage Form K Units (2013-2018)
  • Table 154. Germany Oxaliplatin Sales, by Type K Units (2013-2018)
  • Table 155. Germany Oxaliplatin Sales, by Application K Units (2013-2018)
  • Table 156. Germany Oxaliplatin Sales, by Dosage Form K Units (2013-2018)
  • Table 157. France Oxaliplatin Sales, by Type K Units (2013-2018)
  • Table 158. France Oxaliplatin Sales, by Application K Units (2013-2018)
  • Table 159. France Oxaliplatin Sales, by Dosage Form K Units (2013-2018)
  • Table 160. Italy Oxaliplatin Sales, by Type K Units (2013-2018)
  • Table 161. Italy Oxaliplatin Sales, by Application K Units (2013-2018)
  • Table 162. Italy Oxaliplatin Sales, by Dosage Form K Units (2013-2018)
  • Table 163. United Kingdom Oxaliplatin Sales, by Type K Units (2013-2018)
  • Table 164. United Kingdom Oxaliplatin Sales, by Application K Units (2013-2018)
  • Table 165. United Kingdom Oxaliplatin Sales, by Dosage Form K Units (2013-2018)
  • Table 166. Netherlands Oxaliplatin Sales, by Type K Units (2013-2018)
  • Table 167. Netherlands Oxaliplatin Sales, by Application K Units (2013-2018)
  • Table 168. Netherlands Oxaliplatin Sales, by Dosage Form K Units (2013-2018)
  • Table 169. Rest of Europe Oxaliplatin Sales, by Type K Units (2013-2018)
  • Table 170. Rest of Europe Oxaliplatin Sales, by Application K Units (2013-2018)
  • Table 171. Rest of Europe Oxaliplatin Sales, by Dosage Form K Units (2013-2018)
  • Table 172. MEA Oxaliplatin Sales, by Country K Units (2013-2018)
  • Table 173. MEA Oxaliplatin Sales, by Type K Units (2013-2018)
  • Table 174. MEA Oxaliplatin Sales, by Application K Units (2013-2018)
  • Table 175. MEA Oxaliplatin Sales, by Dosage Form K Units (2013-2018)
  • Table 176. Middle East Oxaliplatin Sales, by Type K Units (2013-2018)
  • Table 177. Middle East Oxaliplatin Sales, by Application K Units (2013-2018)
  • Table 178. Middle East Oxaliplatin Sales, by Dosage Form K Units (2013-2018)
  • Table 179. Africa Oxaliplatin Sales, by Type K Units (2013-2018)
  • Table 180. Africa Oxaliplatin Sales, by Application K Units (2013-2018)
  • Table 181. Africa Oxaliplatin Sales, by Dosage Form K Units (2013-2018)
  • Table 182. North America Oxaliplatin Sales, by Country K Units (2013-2018)
  • Table 183. North America Oxaliplatin Sales, by Type K Units (2013-2018)
  • Table 184. North America Oxaliplatin Sales, by Application K Units (2013-2018)
  • Table 185. North America Oxaliplatin Sales, by Dosage Form K Units (2013-2018)
  • Table 186. United States Oxaliplatin Sales, by Type K Units (2013-2018)
  • Table 187. United States Oxaliplatin Sales, by Application K Units (2013-2018)
  • Table 188. United States Oxaliplatin Sales, by Dosage Form K Units (2013-2018)
  • Table 189. Canada Oxaliplatin Sales, by Type K Units (2013-2018)
  • Table 190. Canada Oxaliplatin Sales, by Application K Units (2013-2018)
  • Table 191. Canada Oxaliplatin Sales, by Dosage Form K Units (2013-2018)
  • Table 192. Mexico Oxaliplatin Sales, by Type K Units (2013-2018)
  • Table 193. Mexico Oxaliplatin Sales, by Application K Units (2013-2018)
  • Table 194. Mexico Oxaliplatin Sales, by Dosage Form K Units (2013-2018)
  • Table 195. Oxaliplatin: by Type(USD/Units)
  • Table 196. Company Basic Information, Sales Area and Its Competitors
  • Table 197. Company Basic Information, Sales Area and Its Competitors
  • Table 198. Company Basic Information, Sales Area and Its Competitors
  • Table 199. Company Basic Information, Sales Area and Its Competitors
  • Table 200. Company Basic Information, Sales Area and Its Competitors
  • Table 201. Company Basic Information, Sales Area and Its Competitors
  • Table 202. Company Basic Information, Sales Area and Its Competitors
  • Table 203. Company Basic Information, Sales Area and Its Competitors
  • Table 204. Company Basic Information, Sales Area and Its Competitors
  • Table 205. Company Basic Information, Sales Area and Its Competitors
  • Table 206. Oxaliplatin: by Type(USD Million)
  • Table 207. Oxaliplatin Mannitol , by Region USD Million (2019-2024)
  • Table 208. Oxaliplatin Glucose Solution , by Region USD Million (2019-2024)
  • Table 209. Oxaliplatin Lactose Solution , by Region USD Million (2019-2024)
  • Table 210. Oxaliplatin Others , by Region USD Million (2019-2024)
  • Table 211. Oxaliplatin: by Application(USD Million)
  • Table 212. Oxaliplatin Colorectal Cancer (XELOX) , by Region USD Million (2019-2024)
  • Table 213. Oxaliplatin Pancreatic Cancer , by Region USD Million (2019-2024)
  • Table 214. Oxaliplatin Gastroesophageal Cancer , by Region USD Million (2019-2024)
  • Table 215. Oxaliplatin Testicular Cancer , by Region USD Million (2019-2024)
  • Table 216. Oxaliplatin Cancer of Unknown Primary Origin , by Region USD Million (2019-2024)
  • Table 217. Oxaliplatin Ovarian Cancer , by Region USD Million (2019-2024)
  • Table 218. Oxaliplatin: by Dosage Form(USD Million)
  • Table 219. Oxaliplatin Sterile Lyophilized Powder (50mg , by Region USD Million (2019-2024)
  • Table 220. South America Oxaliplatin, by Country USD Million (2019-2024)
  • Table 221. South America Oxaliplatin, by Type USD Million (2019-2024)
  • Table 222. South America Oxaliplatin, by Application USD Million (2019-2024)
  • Table 223. South America Oxaliplatin, by Dosage Form USD Million (2019-2024)
  • Table 224. Brazil Oxaliplatin, by Type USD Million (2019-2024)
  • Table 225. Brazil Oxaliplatin, by Application USD Million (2019-2024)
  • Table 226. Brazil Oxaliplatin, by Dosage Form USD Million (2019-2024)
  • Table 227. Argentina Oxaliplatin, by Type USD Million (2019-2024)
  • Table 228. Argentina Oxaliplatin, by Application USD Million (2019-2024)
  • Table 229. Argentina Oxaliplatin, by Dosage Form USD Million (2019-2024)
  • Table 230. Rest of South America Oxaliplatin, by Type USD Million (2019-2024)
  • Table 231. Rest of South America Oxaliplatin, by Application USD Million (2019-2024)
  • Table 232. Rest of South America Oxaliplatin, by Dosage Form USD Million (2019-2024)
  • Table 233. Asia Pacific Oxaliplatin, by Country USD Million (2019-2024)
  • Table 234. Asia Pacific Oxaliplatin, by Type USD Million (2019-2024)
  • Table 235. Asia Pacific Oxaliplatin, by Application USD Million (2019-2024)
  • Table 236. Asia Pacific Oxaliplatin, by Dosage Form USD Million (2019-2024)
  • Table 237. China Oxaliplatin, by Type USD Million (2019-2024)
  • Table 238. China Oxaliplatin, by Application USD Million (2019-2024)
  • Table 239. China Oxaliplatin, by Dosage Form USD Million (2019-2024)
  • Table 240. Japan Oxaliplatin, by Type USD Million (2019-2024)
  • Table 241. Japan Oxaliplatin, by Application USD Million (2019-2024)
  • Table 242. Japan Oxaliplatin, by Dosage Form USD Million (2019-2024)
  • Table 243. India Oxaliplatin, by Type USD Million (2019-2024)
  • Table 244. India Oxaliplatin, by Application USD Million (2019-2024)
  • Table 245. India Oxaliplatin, by Dosage Form USD Million (2019-2024)
  • Table 246. South Korea Oxaliplatin, by Type USD Million (2019-2024)
  • Table 247. South Korea Oxaliplatin, by Application USD Million (2019-2024)
  • Table 248. South Korea Oxaliplatin, by Dosage Form USD Million (2019-2024)
  • Table 249. Taiwan Oxaliplatin, by Type USD Million (2019-2024)
  • Table 250. Taiwan Oxaliplatin, by Application USD Million (2019-2024)
  • Table 251. Taiwan Oxaliplatin, by Dosage Form USD Million (2019-2024)
  • Table 252. Australia Oxaliplatin, by Type USD Million (2019-2024)
  • Table 253. Australia Oxaliplatin, by Application USD Million (2019-2024)
  • Table 254. Australia Oxaliplatin, by Dosage Form USD Million (2019-2024)
  • Table 255. Rest of Asia-Pacific Oxaliplatin, by Type USD Million (2019-2024)
  • Table 256. Rest of Asia-Pacific Oxaliplatin, by Application USD Million (2019-2024)
  • Table 257. Rest of Asia-Pacific Oxaliplatin, by Dosage Form USD Million (2019-2024)
  • Table 258. Europe Oxaliplatin, by Country USD Million (2019-2024)
  • Table 259. Europe Oxaliplatin, by Type USD Million (2019-2024)
  • Table 260. Europe Oxaliplatin, by Application USD Million (2019-2024)
  • Table 261. Europe Oxaliplatin, by Dosage Form USD Million (2019-2024)
  • Table 262. Germany Oxaliplatin, by Type USD Million (2019-2024)
  • Table 263. Germany Oxaliplatin, by Application USD Million (2019-2024)
  • Table 264. Germany Oxaliplatin, by Dosage Form USD Million (2019-2024)
  • Table 265. France Oxaliplatin, by Type USD Million (2019-2024)
  • Table 266. France Oxaliplatin, by Application USD Million (2019-2024)
  • Table 267. France Oxaliplatin, by Dosage Form USD Million (2019-2024)
  • Table 268. Italy Oxaliplatin, by Type USD Million (2019-2024)
  • Table 269. Italy Oxaliplatin, by Application USD Million (2019-2024)
  • Table 270. Italy Oxaliplatin, by Dosage Form USD Million (2019-2024)
  • Table 271. United Kingdom Oxaliplatin, by Type USD Million (2019-2024)
  • Table 272. United Kingdom Oxaliplatin, by Application USD Million (2019-2024)
  • Table 273. United Kingdom Oxaliplatin, by Dosage Form USD Million (2019-2024)
  • Table 274. Netherlands Oxaliplatin, by Type USD Million (2019-2024)
  • Table 275. Netherlands Oxaliplatin, by Application USD Million (2019-2024)
  • Table 276. Netherlands Oxaliplatin, by Dosage Form USD Million (2019-2024)
  • Table 277. Rest of Europe Oxaliplatin, by Type USD Million (2019-2024)
  • Table 278. Rest of Europe Oxaliplatin, by Application USD Million (2019-2024)
  • Table 279. Rest of Europe Oxaliplatin, by Dosage Form USD Million (2019-2024)
  • Table 280. MEA Oxaliplatin, by Country USD Million (2019-2024)
  • Table 281. MEA Oxaliplatin, by Type USD Million (2019-2024)
  • Table 282. MEA Oxaliplatin, by Application USD Million (2019-2024)
  • Table 283. MEA Oxaliplatin, by Dosage Form USD Million (2019-2024)
  • Table 284. Middle East Oxaliplatin, by Type USD Million (2019-2024)
  • Table 285. Middle East Oxaliplatin, by Application USD Million (2019-2024)
  • Table 286. Middle East Oxaliplatin, by Dosage Form USD Million (2019-2024)
  • Table 287. Africa Oxaliplatin, by Type USD Million (2019-2024)
  • Table 288. Africa Oxaliplatin, by Application USD Million (2019-2024)
  • Table 289. Africa Oxaliplatin, by Dosage Form USD Million (2019-2024)
  • Table 290. North America Oxaliplatin, by Country USD Million (2019-2024)
  • Table 291. North America Oxaliplatin, by Type USD Million (2019-2024)
  • Table 292. North America Oxaliplatin, by Application USD Million (2019-2024)
  • Table 293. North America Oxaliplatin, by Dosage Form USD Million (2019-2024)
  • Table 294. United States Oxaliplatin, by Type USD Million (2019-2024)
  • Table 295. United States Oxaliplatin, by Application USD Million (2019-2024)
  • Table 296. United States Oxaliplatin, by Dosage Form USD Million (2019-2024)
  • Table 297. Canada Oxaliplatin, by Type USD Million (2019-2024)
  • Table 298. Canada Oxaliplatin, by Application USD Million (2019-2024)
  • Table 299. Canada Oxaliplatin, by Dosage Form USD Million (2019-2024)
  • Table 300. Mexico Oxaliplatin, by Type USD Million (2019-2024)
  • Table 301. Mexico Oxaliplatin, by Application USD Million (2019-2024)
  • Table 302. Mexico Oxaliplatin, by Dosage Form USD Million (2019-2024)
  • Table 303. Oxaliplatin Sales: by Type(K Units)
  • Table 304. Oxaliplatin Sales Mannitol , by Region K Units (2019-2024)
  • Table 305. Oxaliplatin Sales Glucose Solution , by Region K Units (2019-2024)
  • Table 306. Oxaliplatin Sales Lactose Solution , by Region K Units (2019-2024)
  • Table 307. Oxaliplatin Sales Others , by Region K Units (2019-2024)
  • Table 308. Oxaliplatin Sales: by Application(K Units)
  • Table 309. Oxaliplatin Sales Colorectal Cancer (XELOX) , by Region K Units (2019-2024)
  • Table 310. Oxaliplatin Sales Pancreatic Cancer , by Region K Units (2019-2024)
  • Table 311. Oxaliplatin Sales Gastroesophageal Cancer , by Region K Units (2019-2024)
  • Table 312. Oxaliplatin Sales Testicular Cancer , by Region K Units (2019-2024)
  • Table 313. Oxaliplatin Sales Cancer of Unknown Primary Origin , by Region K Units (2019-2024)
  • Table 314. Oxaliplatin Sales Ovarian Cancer , by Region K Units (2019-2024)
  • Table 315. Oxaliplatin Sales: by Dosage Form(K Units)
  • Table 316. Oxaliplatin Sales Sterile Lyophilized Powder (50mg , by Region K Units (2019-2024)
  • Table 317. South America Oxaliplatin Sales, by Country K Units (2019-2024)
  • Table 318. South America Oxaliplatin Sales, by Type K Units (2019-2024)
  • Table 319. South America Oxaliplatin Sales, by Application K Units (2019-2024)
  • Table 320. South America Oxaliplatin Sales, by Dosage Form K Units (2019-2024)
  • Table 321. Brazil Oxaliplatin Sales, by Type K Units (2019-2024)
  • Table 322. Brazil Oxaliplatin Sales, by Application K Units (2019-2024)
  • Table 323. Brazil Oxaliplatin Sales, by Dosage Form K Units (2019-2024)
  • Table 324. Argentina Oxaliplatin Sales, by Type K Units (2019-2024)
  • Table 325. Argentina Oxaliplatin Sales, by Application K Units (2019-2024)
  • Table 326. Argentina Oxaliplatin Sales, by Dosage Form K Units (2019-2024)
  • Table 327. Rest of South America Oxaliplatin Sales, by Type K Units (2019-2024)
  • Table 328. Rest of South America Oxaliplatin Sales, by Application K Units (2019-2024)
  • Table 329. Rest of South America Oxaliplatin Sales, by Dosage Form K Units (2019-2024)
  • Table 330. Asia Pacific Oxaliplatin Sales, by Country K Units (2019-2024)
  • Table 331. Asia Pacific Oxaliplatin Sales, by Type K Units (2019-2024)
  • Table 332. Asia Pacific Oxaliplatin Sales, by Application K Units (2019-2024)
  • Table 333. Asia Pacific Oxaliplatin Sales, by Dosage Form K Units (2019-2024)
  • Table 334. China Oxaliplatin Sales, by Type K Units (2019-2024)
  • Table 335. China Oxaliplatin Sales, by Application K Units (2019-2024)
  • Table 336. China Oxaliplatin Sales, by Dosage Form K Units (2019-2024)
  • Table 337. Japan Oxaliplatin Sales, by Type K Units (2019-2024)
  • Table 338. Japan Oxaliplatin Sales, by Application K Units (2019-2024)
  • Table 339. Japan Oxaliplatin Sales, by Dosage Form K Units (2019-2024)
  • Table 340. India Oxaliplatin Sales, by Type K Units (2019-2024)
  • Table 341. India Oxaliplatin Sales, by Application K Units (2019-2024)
  • Table 342. India Oxaliplatin Sales, by Dosage Form K Units (2019-2024)
  • Table 343. South Korea Oxaliplatin Sales, by Type K Units (2019-2024)
  • Table 344. South Korea Oxaliplatin Sales, by Application K Units (2019-2024)
  • Table 345. South Korea Oxaliplatin Sales, by Dosage Form K Units (2019-2024)
  • Table 346. Taiwan Oxaliplatin Sales, by Type K Units (2019-2024)
  • Table 347. Taiwan Oxaliplatin Sales, by Application K Units (2019-2024)
  • Table 348. Taiwan Oxaliplatin Sales, by Dosage Form K Units (2019-2024)
  • Table 349. Australia Oxaliplatin Sales, by Type K Units (2019-2024)
  • Table 350. Australia Oxaliplatin Sales, by Application K Units (2019-2024)
  • Table 351. Australia Oxaliplatin Sales, by Dosage Form K Units (2019-2024)
  • Table 352. Rest of Asia-Pacific Oxaliplatin Sales, by Type K Units (2019-2024)
  • Table 353. Rest of Asia-Pacific Oxaliplatin Sales, by Application K Units (2019-2024)
  • Table 354. Rest of Asia-Pacific Oxaliplatin Sales, by Dosage Form K Units (2019-2024)
  • Table 355. Europe Oxaliplatin Sales, by Country K Units (2019-2024)
  • Table 356. Europe Oxaliplatin Sales, by Type K Units (2019-2024)
  • Table 357. Europe Oxaliplatin Sales, by Application K Units (2019-2024)
  • Table 358. Europe Oxaliplatin Sales, by Dosage Form K Units (2019-2024)
  • Table 359. Germany Oxaliplatin Sales, by Type K Units (2019-2024)
  • Table 360. Germany Oxaliplatin Sales, by Application K Units (2019-2024)
  • Table 361. Germany Oxaliplatin Sales, by Dosage Form K Units (2019-2024)
  • Table 362. France Oxaliplatin Sales, by Type K Units (2019-2024)
  • Table 363. France Oxaliplatin Sales, by Application K Units (2019-2024)
  • Table 364. France Oxaliplatin Sales, by Dosage Form K Units (2019-2024)
  • Table 365. Italy Oxaliplatin Sales, by Type K Units (2019-2024)
  • Table 366. Italy Oxaliplatin Sales, by Application K Units (2019-2024)
  • Table 367. Italy Oxaliplatin Sales, by Dosage Form K Units (2019-2024)
  • Table 368. United Kingdom Oxaliplatin Sales, by Type K Units (2019-2024)
  • Table 369. United Kingdom Oxaliplatin Sales, by Application K Units (2019-2024)
  • Table 370. United Kingdom Oxaliplatin Sales, by Dosage Form K Units (2019-2024)
  • Table 371. Netherlands Oxaliplatin Sales, by Type K Units (2019-2024)
  • Table 372. Netherlands Oxaliplatin Sales, by Application K Units (2019-2024)
  • Table 373. Netherlands Oxaliplatin Sales, by Dosage Form K Units (2019-2024)
  • Table 374. Rest of Europe Oxaliplatin Sales, by Type K Units (2019-2024)
  • Table 375. Rest of Europe Oxaliplatin Sales, by Application K Units (2019-2024)
  • Table 376. Rest of Europe Oxaliplatin Sales, by Dosage Form K Units (2019-2024)
  • Table 377. MEA Oxaliplatin Sales, by Country K Units (2019-2024)
  • Table 378. MEA Oxaliplatin Sales, by Type K Units (2019-2024)
  • Table 379. MEA Oxaliplatin Sales, by Application K Units (2019-2024)
  • Table 380. MEA Oxaliplatin Sales, by Dosage Form K Units (2019-2024)
  • Table 381. Middle East Oxaliplatin Sales, by Type K Units (2019-2024)
  • Table 382. Middle East Oxaliplatin Sales, by Application K Units (2019-2024)
  • Table 383. Middle East Oxaliplatin Sales, by Dosage Form K Units (2019-2024)
  • Table 384. Africa Oxaliplatin Sales, by Type K Units (2019-2024)
  • Table 385. Africa Oxaliplatin Sales, by Application K Units (2019-2024)
  • Table 386. Africa Oxaliplatin Sales, by Dosage Form K Units (2019-2024)
  • Table 387. North America Oxaliplatin Sales, by Country K Units (2019-2024)
  • Table 388. North America Oxaliplatin Sales, by Type K Units (2019-2024)
  • Table 389. North America Oxaliplatin Sales, by Application K Units (2019-2024)
  • Table 390. North America Oxaliplatin Sales, by Dosage Form K Units (2019-2024)
  • Table 391. United States Oxaliplatin Sales, by Type K Units (2019-2024)
  • Table 392. United States Oxaliplatin Sales, by Application K Units (2019-2024)
  • Table 393. United States Oxaliplatin Sales, by Dosage Form K Units (2019-2024)
  • Table 394. Canada Oxaliplatin Sales, by Type K Units (2019-2024)
  • Table 395. Canada Oxaliplatin Sales, by Application K Units (2019-2024)
  • Table 396. Canada Oxaliplatin Sales, by Dosage Form K Units (2019-2024)
  • Table 397. Mexico Oxaliplatin Sales, by Type K Units (2019-2024)
  • Table 398. Mexico Oxaliplatin Sales, by Application K Units (2019-2024)
  • Table 399. Mexico Oxaliplatin Sales, by Dosage Form K Units (2019-2024)
  • Table 400. Oxaliplatin: by Type(USD/Units)
  • Table 401. Research Programs/Design for This Report
  • Table 402. Key Data Information from Secondary Sources
  • Table 403. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Oxaliplatin: by Type USD Million (2013-2018)
  • Figure 5. Global Oxaliplatin: by Application USD Million (2013-2018)
  • Figure 6. Global Oxaliplatin: by Dosage Form USD Million (2013-2018)
  • Figure 7. South America Oxaliplatin Share (%), by Country
  • Figure 8. Asia Pacific Oxaliplatin Share (%), by Country
  • Figure 9. Europe Oxaliplatin Share (%), by Country
  • Figure 10. MEA Oxaliplatin Share (%), by Country
  • Figure 11. North America Oxaliplatin Share (%), by Country
  • Figure 12. Global Oxaliplatin: by Type K Units (2013-2018)
  • Figure 13. Global Oxaliplatin: by Application K Units (2013-2018)
  • Figure 14. Global Oxaliplatin: by Dosage Form K Units (2013-2018)
  • Figure 15. South America Oxaliplatin Share (%), by Country
  • Figure 16. Asia Pacific Oxaliplatin Share (%), by Country
  • Figure 17. Europe Oxaliplatin Share (%), by Country
  • Figure 18. MEA Oxaliplatin Share (%), by Country
  • Figure 19. North America Oxaliplatin Share (%), by Country
  • Figure 20. Global Oxaliplatin: by Type USD/Units (2013-2018)
  • Figure 21. Global Oxaliplatin share by Players 2018 (%)
  • Figure 22. Global Oxaliplatin share by Players (Top 3) 2018(%)
  • Figure 23. Global Oxaliplatin share by Players (Top 5) 2018(%)
  • Figure 24. BCG Matrix for key Companies
  • Figure 25. Sanofi (France) Revenue, Net Income and Gross profit
  • Figure 26. Sanofi (France) Revenue: by Geography 2018
  • Figure 27. Yakult honsha (Japan) Revenue, Net Income and Gross profit
  • Figure 28. Yakult honsha (Japan) Revenue: by Geography 2018
  • Figure 29. Dr. Reddy's Laboratories (India) Revenue, Net Income and Gross profit
  • Figure 30. Dr. Reddy's Laboratories (India) Revenue: by Geography 2018
  • Figure 31. Sun Pharmaceutical (India) Revenue, Net Income and Gross profit
  • Figure 32. Sun Pharmaceutical (India) Revenue: by Geography 2018
  • Figure 33. Teva Pharmaceutical Industries (Israel) Revenue, Net Income and Gross profit
  • Figure 34. Teva Pharmaceutical Industries (Israel) Revenue: by Geography 2018
  • Figure 35. Fresenius Kabi (Germany) Revenue, Net Income and Gross profit
  • Figure 36. Fresenius Kabi (Germany) Revenue: by Geography 2018
  • Figure 37. Hospira (United States) Revenue, Net Income and Gross profit
  • Figure 38. Hospira (United States) Revenue: by Geography 2018
  • Figure 39. Mylan (United States) Revenue, Net Income and Gross profit
  • Figure 40. Mylan (United States) Revenue: by Geography 2018
  • Figure 41. Jiangsu Hengrui Medicine (China) Revenue, Net Income and Gross profit
  • Figure 42. Jiangsu Hengrui Medicine (China) Revenue: by Geography 2018
  • Figure 43. Nanjing Pharmaceutical Factory (China) Revenue, Net Income and Gross profit
  • Figure 44. Nanjing Pharmaceutical Factory (China) Revenue: by Geography 2018
  • Figure 45. Global Oxaliplatin: by Type USD Million (2019-2024)
  • Figure 46. Global Oxaliplatin: by Application USD Million (2019-2024)
  • Figure 47. Global Oxaliplatin: by Dosage Form USD Million (2019-2024)
  • Figure 48. South America Oxaliplatin Share (%), by Country
  • Figure 49. Asia Pacific Oxaliplatin Share (%), by Country
  • Figure 50. Europe Oxaliplatin Share (%), by Country
  • Figure 51. MEA Oxaliplatin Share (%), by Country
  • Figure 52. North America Oxaliplatin Share (%), by Country
  • Figure 53. Global Oxaliplatin: by Type K Units (2019-2024)
  • Figure 54. Global Oxaliplatin: by Application K Units (2019-2024)
  • Figure 55. Global Oxaliplatin: by Dosage Form K Units (2019-2024)
  • Figure 56. South America Oxaliplatin Share (%), by Country
  • Figure 57. Asia Pacific Oxaliplatin Share (%), by Country
  • Figure 58. Europe Oxaliplatin Share (%), by Country
  • Figure 59. MEA Oxaliplatin Share (%), by Country
  • Figure 60. North America Oxaliplatin Share (%), by Country
  • Figure 61. Global Oxaliplatin: by Type USD/Units (2019-2024)
Some of the key companies/manufacturers profiled in the report
  • Sanofi (France)
  • Yakult honsha (Japan)
  • Dr. Reddy's Laboratories (India)
  • Sun Pharmaceutical (India)
  • Teva Pharmaceutical Industries (Israel)
  • Fresenius Kabi (Germany)
  • Hospira (United States)
  • Mylan (United States)
  • Jiangsu Hengrui Medicine (China)
  • Nanjing Pharmaceutical Factory (China)
Additional players considered in the study are as follows:
Hisun Pharmaceutical (United States) , Chia Tai-Tianqing Pharmaceutical Holdings Co., Ltd (China) , Jiangsu Aosaikang Pharmaceutical (China) , Qilu Pharmaceutical (China)
Select License Type
Sample Report Enquiry Before Buy Request Discount

Speak with Analyst

Want to find out more about this report?

Get Free Consultation